Developing our portfolio through Research and Development

Teva’s Research and Development has a specific focus on disorders of the central nervous system, pain and respiratory conditions.

We are committed to researching and developing medicines to meet the needs of patients and families affected by disorders of the central nervous system, including neurological and neurodegenerative diseases, pain, and movement disorders.

Physically, financially and emotionally destructive to both patients and their families, neurodegenerative diseases represent a huge burden to healthcare systems globally. We are deepening our understanding of neurodegenerative disorders so that we can find molecules that allow us to change the course of disease  and improve the quality of life for patients.

Teva is also developing innovative solutions in headache and migraine, and socially responsible pain treatments.

Our R&D group is developing a focused portfolio of solutions that looks across the spectrum of pain states, including chronic nociceptive pain, cancer pain, chronic neuropathic pain and migraine.

We are working hard to bring relief to people suffering from migraines – and in particular the disruption to quality of life that chronic or high frequency episodic migraine brings.

We are bringing more relief to patients by enhancing our opioid-based treatments. At the same time, we are addressing some of the key challenges associated with opioids.

The focus of our R&D efforts in respiratory is on breath-activated inhaled therapies for asthma and COPD, where incorrect inhaler technique and non-adherence has been shown to be associated with poor asthma control, as well as targeted biologics for uncontrolled asthma. E-connectivity is also a key pillar of our respiratory focus.

Asthma has a significant impact on patients’ quality of life because of the symptoms suffered, the amount of medication required and the constant fear of exposure to triggers or events.  The economic and societal burden of asthma is immense.

Yet, asthma is manageable. There are two key issues, and this is where Teva is focused. They are 1) treatment adherence and compliance, and 2) treating asthma when it is not controlled despite the use of optimal therapy.

We want to give people a more effective role in their own treatment – and by doing so, put them back in charge of their lives. This is why we take our inspiration from the everyday experiences of patients coping with respiratory disease. And the more we understand the reality of how treatments work in the world of patients, the easier it becomes to find those pivotal points where a pragmatic change – or an innovative new solution – can support healthcare professionals in winning the fight for breath.

Every branch of our development process has the goal of improving patient outcomes at its heart. This is our promise.

Date of preparation: May 2018
Ref: IE/CPE/18/0005